Slowly, but surely, cloud computing is changing the way that technology is applied. The analysts at Deutsche Bank in a new research piece, have taken a deep-dive into the model and note that evolving software technologies have and continue to create new economic value. They are also of the opinion that subscription and consumption-based models will grow as a share of information technology spending, and they are cannibalizing traditional software at an accelerating pace. The analysts focused their work on companies that lean heavily to the domestic market, as our economy looks to lead the world forward. Here are the top cloud computing stock to buy at Deutsche Bank.
Adobe Systems Inc. (NASDAQ: ADBE) has been named by Gartner as a leader in their new report ��agic Quadrant for Web Management.��Adobe was positioned highest in ability to execute and completeness of vision in the report. The evaluation criteria for a vendor�� ability to execute included product/service, overall viability, sales execution/pricing, market responsiveness and track record, marketing execution, customer experience and operations. Deutsche Bank has a $52 price target for the stock. The Thomson/First Call estimate is at $51.
Hot Cheap Companies To Watch In Right Now: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion:- [By David Williamson]
In this video, health-care analyst David Williamson takes a look at the tremendous success of the�Bluebird Bio (NASDAQ: BLUE ) �IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 33.61 percent to $34.86 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 34.74 percent to $35.15 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
5 Best Information Technology Stocks To Buy For 2014: Pacer International Inc.(PACR)
Pacer International, Inc., together with its subsidiaries, provides asset-light transportation and logistics services primarily in North America, Asia, Europe, Australia, South America, and Africa. It operates in two segments, Intermodal and Logistics. The Intermodal segment offers intermodal rail transportation, local cartage and trucking, intermodal marketing services, container capacity, on-site operational services, and door-to-door shipment management services. As of December 31, 2011, its equipment fleet consisted of 1,592 double-stack railcars, 18,183 containers, and 12,783 chassis. The Logistics segment provides highway brokerage, warehousing and distribution, international freight forwarding, ocean and air shipping, and supply chain management services, as well as offers non-vessel-operating common carrier to end-user customers. The company markets and supports its services to cargo owners, steamship lines, truckload carriers, truck brokers, and freight forwarders , as well as other third party transportation service providers, such as intermodal marketing companies, third-party logistics companies, and shippers? agents through its direct sales and customer service representatives. Pacer International, Inc. was founded in 1974 and is headquartered in Dublin, Ohio.
Advisors' Opinion:- [By Jake L'Ecuyer]
XPO Logistics (NYSE: XPO) shot up 7.06 percent to $30.01 after the company announced its plans to acquire Pacer International (NASDAQ: PACR) in a deal valued at $335 million.
- [By Vera Yuan]
Pacer International, Inc. (PACR) was acquired by XPO Logistics, Inc. which remains in our portfolio. We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott. We eliminated our position in convenience store distributor Core- Mark Holding Co., Inc.( CORE) as the stock rose almost 40% over the last year and reached our estimate of intrinsic value.
5 Best Information Technology Stocks To Buy For 2014: Recon Technology Ltd.(RCON)
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People?s Republic of China. The company offers equipment, tools, and other hardware related to oilfield production and management; and develop and sell industrial automation control and information solutions. Its oil and gas production and transportation equipment comprise heating furnaces, burners, and separators. Recon Technology, Ltd.?s oil and gas development tools and equipment include packers of fracturing, production packers, and water injection packers; and oil and gas production increasing techniques consist of fissure shaper technique to increase perforation depth, sand prevention in oil and water well technique, water locating and plugging technique, fracture acidizing technique, and electronic broken-down service. Its automation systems and services comprise pumping unit controllers that monitors the pumping units and co llects data for load, pressure, voltage, startup, and shutdown control; RTU for monitoring natural gas wells and collecting gas well pressure data; wireless dynamometer and wireless pressure gauge; electric multi-way valve for oilfield metering station flow control; and natural gas flow computer system to measure the flow. The company?s automation systems and services also consist of Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil, and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead area and measure station area; and technique service for digital oilfield transformation. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By James E. Brumley]
Anybody who was lucky enough to get into a Recon Technology, Ltd. (NASDAQ:RCON) position before October 7th, then congratulations - you're up big-time. Now get out. Instead, a better use of that capital is Mitek Systems, Inc. (NASDAQ:MITK). While RCON is overbought and ripe for a pullback, MITK is itching to stage a breakout.
5 Best Information Technology Stocks To Buy For 2014: Endocan Corp (ENDO)
Endocan Corp, formerly The X-Change Corporation, incorporated on October 4, 2000, offers nutraceuticals and cosmetics in the United States. The Company provides lip balms, eczema moisturizing cream, sunscreen, and anti-ageing serum under the Phytiva brand name. The Company specializes in developing all natural, organic, bio hemp health, beauty, and cosmetics products.
The Phytiva serum uses only natural ingredients, including, but not limited to, hemp oil extract. The Company specializes in Cannabinoid-based extracts and products that target medical cannabis, nutraceutical, cosmeceutical, and social usage solutions through multiple Phytiva Brand product lines, products, and services.
Advisors' Opinion:- [By Peter Graham]
Next Generation Energy Corp (OTCMKTS: NGMC) and Dutch Gold Resources, Inc (OTCMKTS: DGRI) are the latest small cap stocks to announce their entry into the marijuana business while peer Endocan Corp (OTCMKTS: ENDO) sees some paid promotions or investor relations activities, but otherwise remains quiet. So will investors and traders alike achieve a high with any of these small cap marijuana stocks? Here is a quick reality check:
No comments:
Post a Comment